Data Sheet (Cat.No.T22012)

TargetMol

7BIO

Chemical Properties



CAS No. : 916440-85-2

Formula: C16H10BrN3O2

Molecular Weight: 356.17

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
Targets(IC50)	FLT,CDK,Aurora Kinase,DYRK,GSK-3

Solubility Information

Solubility	Ethanol: Soluble DMSO: 83.33 mg/mL (233.96 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: < 8.33 mg/mL (23.39 mM),Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8.33 mg/mL (23.39 mM),Solution. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8076 mL	14.0382 mL	28.0765 mL
5 mM	0.5615 mL	2.8076 mL	5.6153 mL
10 mM	0.2808 mL	1.4038 mL	2.8076 mL
50 mM	0.0562 mL	0.2808 mL	0.5615 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ribas J, Bettayeb K, Ferandin Y, et al. 7-Bromoindirubin-3′-oxime induces caspase-independent cell death[J]. Oncogene, 2006, 25(47): 6304-6318.

Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, et al. Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases[J]. ACS medicinal chemistry letters, 2012, 4(1): 22-26.

Myrianthopoulos V, Magiatis P, Ferandin Y, et al. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins[J]. Journal of medicinal chemistry, 2007, 50(17): 4027-4037.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481